Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study

• Karen Liao ,

  Roles Conceptualization, Formal analysis, Investigation, Writing – original draft, Writing – review & editing

  * E-mail: karen.x.liao@gsk.com

  Affiliation Immunogenicity Group, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  https://orcid.org/0000-0002-4685-7179

  ⨯
• Keguan Chen,

  Roles Investigation

  Affiliation Immunogenicity Group, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Sara Brett,

  Roles Data curation

  Affiliation Oncology Cell Therapy, Oncology R&D, Stevenage, United Kingdom

  ⨯
• Andrew Gehman,

  Roles Formal analysis

  Affiliation Research Statistics, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Ann M. Schwartz,

  Roles Methodology

  Affiliation Immunogenicity Group, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• George R. Gunn,

  Roles Resources, Writing – review & editing

  Affiliation Immunogenicity Group, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Stephen L. DeWall

  Roles Conceptualization, Writing – review & editing

  Current address: Spark Therapeutics, Philadelphia, PA, United States of America

  Affiliation Immunogenicity Group, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯